Vorinostat for GVHD prevention in young adults with non-cancer conditions
Treatments studied
Part of Immune system & allergy clinical trials.
This trial tests if the drug vorinostat can help prevent graft-versus-host disease (GVHD) in adolescents and young adults undergoing a stem cell transplant for non-cancerous blood, immune, or metabolic disorders. GVHD is a common complication where donor cells attack the recipient's body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a non-cancerous condition that needs a stem cell transplant, like an immune disorder, metabolic disease, severe red blood cell disorder, or inherited bone marrow failure.
- A suitable donor is available (matched sibling, matched unrelated donor, or half-matched donor).
- Your lungs, kidneys, liver, heart, and overall health are good enough for the transplant procedure.
- You agree to use effective birth control during treatment and for 6 months (females) or 3 months (males) after the last dose.
- You are not pregnant or breastfeeding, and you do not have active infections like HIV, hepatitis B or C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different medicines (ATG-thymoglobulin and ATLG-grafalon) to prevent graft-versus-host disease (GVHD) after a stem cell transplant. It is for older adults with certain blood cancers who have a matched unrelated donor.
This trial tests a new way to prevent graft-versus-host disease (GvHD), a common complication after a stem cell transplant. It is for people with certain blood cancers who are getting a stem cell transplant from a half-matched family member or unrelated donor.
This Phase 1 study tests a new combination of medicines to prevent graft-versus-host disease (GVHD) after an allogeneic stem cell transplant. If it works well, it may lower the chance and severity of GVHD, which can affect skin, liver, and the gut.
This trial tests a combination of four medicines (cyclophosphamide, abatacept, vedolizumab, and ruxolitinib) to prevent graft-versus-host disease (GVHD) after a stem cell transplant for children and young adults with certain blood cancers. The goal is to see if this approach reduces the risk of GVHD, a serious complication where donor cells attack the body.
This trial tests whether adding VIC-1911 to standard medications (cyclophosphamide and sirolimus) can help prevent graft-versus-host disease in children receiving a half-matched stem cell transplant from a family donor.
This trial tests a new approach to prevent graft-versus-host disease (GVHD) after a stem cell transplant from a matched donor. It is for people aged 60 or older with a blood cancer or serious blood disorder who are getting a reduced-intensity conditioning regimen.
Hear when a new GVHD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.